Document Detail


Nebivolol for the treatment of heart failure.
MedLine Citation:
PMID:  21546638     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Purpose The pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of nebivolol are reviewed. Summary Nebivolol, a third-generation, highly β(1)-specific β-blocker, is labeled for the treatment of hypertension in the United States. In addition to its β-blocking effects, nebivolol has been shown to increase endothelin-dependent nitric oxide, giving it a unique peripheral vasodilatory action. Nebivolol is extensively metabolized by cytochrome P-450 isoenzyme 2D6. In patients with heart failure, certain β-blockers antagonize excessive adrenergic stimulation and can slow the progression of the disease. Clinical trials have compared nebivolol at target dosages of 5 and 10 mg once daily with placebo and, in small trials, with carvedilol in the treatment of adults with chronic heart failure. Nebivolol appears to have beneficial effects in patients with heart failure, including improvements in left ventricular ejection fraction, left ventricular volumes, and exercise capacity. In addition, the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure showed a reduction in morbidity and mortality after treatment with nebivolol when compared with placebo, though this effect appeared to be less than that of other β-blockers currently recommended for the treatment of heart failure. Nebivolol was well tolerated in all clinical trials, with the most frequently reported adverse events including bradycardia, hypotension, and dizziness. To date, no large clinical trials have compared nebivolol with currently recommended β-blockers in patients with heart failure. Conclusion Nebivolol has beneficial effects in heart failure but cannot be considered equivalent to other currently accepted therapies.
Authors:
Allison S Dery; Leslie A Hamilton; Jessica A Starr
Related Documents :
21127708 - Genetic variation of vkorc1 and cyp4f2 genes related to warfarin maintenance dose in pa...
11827918 - Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary interv...
24947238 - Mouse models of heart failure: cell signaling and cell survival.
3354438 - Usefulness of lactate dehydrogenase and lactate dehydrogenase isoenzymes for diagnosis ...
10356598 - Qt dispersion and late potentials during doxorubicin therapy for non-hodgkin's lymphoma.
9101118 - Time course of lysophosphatidylcholine release from ischemic human myocardium parallels...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists     Volume:  68     ISSN:  1535-2900     ISO Abbreviation:  Am J Health Syst Pharm     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-05-06     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9503023     Medline TA:  Am J Health Syst Pharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  879-86     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Efforts to support the development of fusidic Acid in the United States.
Next Document:  Severe hepatotoxicity and probable hepatorenal syndrome associated with sulfadiazine.